1 Title Page

3

2 Vitamin D deficiency and toxicity across 2018 to 2022 in several cities of

Ecuador: interrupted time series and a cross-sectional study

4 Short Title: Vitamin D deficiency and toxicity across 2018 to 2022 in several cities

5 of Ecuador

6 Authors:

- Camilo Zurita-Salinas^{a,b}, Betzabé Tello^{c,d}, Iván Dueñas-Espín^e, Jeannete
 Zurita^{a,c}, William Acosta^c, Cristina Aguilera León^a, Andrés Andrade-Muñoz^c, José
- 9 Pareja-Maldonado^c.
- ¹⁰ ^a Biomedical Research Unit. Zurita & Zurita Laboratories, Quito, Ecuador.

¹¹ ^b Facultad de Ciencias Médicas. Universidad Central del Ecuador, Quito, Ecuador.

- ^c Facultad de Medicina. Pontificia Universidad Católica del Ecuador, Quito,
 Ecuador.
- ^d Centro de Investigación para la Salud en América Latina CISeAL, Quito,
 Ecuador.
- ^e Instituto de Salud Pública. Pontificia Universidad Católica del Ecuador, Quito,
 Ecuador.

18 * Corresponding author

- 19 Betzabé Tello, Centro de Investigación para la Salud en América Latina CISeAL,
- 20 Facultad de Medicina. Pontificia Universidad Católica del Ecuador, Quito, Ecuador,
- 21 Av. 12 de octubre 1076 and Roca, postal code: 170525, pone number: (593) (02)
- 22 2991700 Ext 2881, Quito Ecuador; e-mail: <u>bmtello@puce.edu.ec</u>

23

It is made available under a CC-BY-ND 4.0 International license .

24 Abstract

Objectives: to identify differences in mean vitamin D concentrations in samples obtained from a private laboratory in the city of Quito, and to explore their relationship with the pre-pandemic and pandemic periods spanning from 2018 to 2022.

Design: A combination of an interrupted time series design and a retrospectivecross-sectional approach

Setting and participants: The study involved 9,285 participants who had their 25 hydroxyvitamin D (25(OH)D) levels tested at a well-known private laboratory in
 Quito, Ecuador, from 2018 to 2022.

Primary and secondary outcome measures: The 25(OH)D levels were analyzed and assessed for correlations with both age and the year in which the measurements were taken.

Results: The mean 25-hydroxyvitamin D (25(OH)D) level was 27.53 ng/mL (\pm 14.11). Approximately 64.58% of participants had insufficient levels, below 20 ng/mL, and 0.62% showed potential harm from excess 25(OH)D, with levels over 100 ng/mL. The analysis indicated a significant monthly increase of 0.133 units in 25(OH)D levels (p=0.006). However, the period after March 2020, compared to before, saw a non-significant decrease of 1.605 units in mean 25(OH)D levels (p=0.477).

44 **Conclusions:** The study's findings indicate a significant prevalence of 25-45 hydroxyvitamin D (25(OH)D) deficiency, underscoring the necessity for 46 preventative measures. Nevertheless, the rise in cases of vitamin D toxicity is 47 concerning, emphasizing the importance of prudent vitamin D supplement 48 prescriptions and public education against self-medication. For efficient resource 49 allocation and targeting those with higher risks, it may be advantageous to 50 concentrate vitamin D testing on specific population groups.

51

52 **Keywords:** 25-hydroxyvitamin-D; vitamin D deficiency; vitamin d toxicity,

53 hypervitaminosis d, overdose.

It is made available under a CC-BY-ND 4.0 International license .

54 Introduction

Vitamin D, a prohormone, has a crucial influence on a multitude of biological processes, encompassing immunological responses, phosphocalcic metabolism, and detoxification. Recent revelations regarding the diverse functions of vitamin D have engendered escalating interest among the scientific community, fostering an ongoing commitment to further research in this realm. The intricate regulation of vitamin D is governed by a complex interplay of genetic and environmental factors, underscoring the multifaceted nature of its mechanisms [1].

62 The primary source of vitamin D in humans stems from the interaction of UVB radiation with the skin during sunlight exposure. When the skin is exposed to 63 ultraviolet radiation, a photochemical reaction occurs; cleaving carbon bonds in the 64 precursor of vitamin D, 7-dehydrocholesterol, to form pre-vitamin D2. Subsequent 65 temperature-dependent molecular rearrangements facilitate the production of 66 67 active vitamin D, which can be stored within the body for several months due to its liposoluble nature[2]. In addition to sunlight, vitamin D can also be obtained from 68 69 external sources such as certain foods and supplements[1].

70 Defining the optimal level of 25(OH)D, the major circulating form of vitamin D, remains a topic of ongoing debate[3]. Some studies have highlighted a potential 71 overestimation of vitamin D deficiency prevalence in the population, fueling 72 controversy over the necessity of supplementation in healthy individuals[3]. 73 Notably, The Endocrine Society defines deficiency as <20 ng/ml, insufficiency as 74 21-29 ng/ml, and optimal levels as >30 ng/ml, while the Institute of Medicine 75 (Health and Medicine Division of the National Academies) considers deficiency as 76 <12 ng/ml, insufficiency as 12-20 ng/ml, and optimal levels as >20 ng/ml. 77 Furthermore, The American Association of Clinical Endocrinologists defines 78 79 deficiency as < 30 ng/ml and optimal levels as 30-50 ng/ml[4]. Globally, an estimated 15.7% of the population suffers from a vitamin D deficit, with South 80 America exhibiting a higher prevalence of 34.75%[4,5]. No previous studies in 81 Ecuador have considered altitude and the pandemic. Quito, Ecuador's capital, sits 82 83 at 2850 meters above sea level.

It is made available under a CC-BY-ND 4.0 International license .

During the COVID-19 pandemic, several studies have documented significant lifestyle changes among individuals, including modifications in dietary patterns, reduced participation in outdoor activities, and a decline in physical exercise[6]. These lifestyle shifts have the potential to impact vitamin D synthesis, as they may serve as contributing factors[6,7].

Vitamin D deficiency has been linked to acute and chronic diseases that affect not only the skeletal system but also other physiological systems. Timely treatment for individuals with vitamin D deficiency can potentially improve their quality of life and reduce associated health risks[8].

The objective of this study was to identify differences in mean vitamin D concentrations in samples obtained from a private laboratory in the city of Quito, and to explore their relationship with the pre-pandemic and pandemic periods spanning from 2018 to 2022.

97 Methods

98 Design

99 A combination of an interrupted time series design and a retrospective crosssectional approach was employed in this study to assess shifts in population-level 100 101 25-hydroxyvitamin D (25(OH)D) status and associated toxicity in Ecuador, pre and post-onset of the COVID-19 pandemic. Data were collated at multiple time 102 103 points through cross-sectional measures of previously collected data prior to and following the pandemic's onset. This design facilitated the appraisal of long-term 104 trends and the potential influence of the pandemic on 25-hydroxyvitamin D 105 (25(OH)D) levels and associated toxicity. 106

107 Settings

This study was conducted primarily in a large private laboratory in Quito, Ecuador. A diverse cohort of patients was included, most of whom had their 25hydroxyvitamin D (25(OH)D) levels tested at the request of their physicians. These people came from various cities, primarily from Quito, Ibarra, Ambato, and Santo

It is made available under a CC-BY-ND 4.0 International license .

Domingo. Data from 2018 to 2022 were analyzed, with the exception that for the year 2022 only data from January were included.

114 Study population and sample size

The study population comprised people who had their 25-hydroxyvitamin D 115 (25(OH)D) levels tested at a large private laboratory in Quito, Ecuador, between 116 the years 2018 and 2022. A vast majority of these tests were performed at the 117 request of the patients' physicians. Patients from various cities such as Quito, 118 Ambato, Ibarra, and Santo Domingo contributed to the diversity of the sample. The 119 total sample size was 9,285. By the year 2022, the sample included only those 120 people whose vitamin D levels were tested in January. Additionally, we performed 121 a secondary analysis in a subsample of 919 patients in which we collected 122 information about chronic diseases and medications in order to calculate the 123 prevalence of inadequate levels of vitamin D in people with and without chronic 124 125 diseases.

126 Data collection procedures

There is a consensus among experts regarding the use of serum/plasma 25(OH)D 127 128 concentration as the preferred method to evaluate vitamin D status. It is widely agreed that this measurement reflects the combined contributions of diet and 129 dermal synthesis. The choice of 25(OH)D is justified by its advantageous 130 characteristics, including its extended half-life of 15 days, relative stability, 131 132 abundant presence in the blood, and responsiveness to recent endogenous vitamin D production and exogenous intake from diet or supplements[1,9]. The 133 134 determination of 25-hydroxyvitamin D Total in human plasma was assessed using the ELFA (Enzyme Linked Fluorescent Assay) technique. The measurements were 135 136 performed using the VIDAS laboratory machine, employing reagents manufactured by Biomerieux. Following the completion of the assay, the results were 137 automatically analyzed by the computer. 138

It is made available under a CC-BY-ND 4.0 International license .

The instrument automatically calculated the results using stored calibration curves based on a 4-parameter logistics model. The results were expressed in either ng/mL or nmol/L.

The VIDAS 25 OH Vitamin D TOTAL measurement range spanned from 8.1 ng/mL to 126.0 ng/mL. Results below the lower limit of the measurement range were reported as "< 8.1 ng/mL," while values above the upper limit were reported as "> 126.0 ng/mL.". In this study, the reference value of < 20ng/mL was adopted to classify laboratory samples as "inadequate levels", encompassing values indicating deficiency and insufficiency. Furthermore, values exceeding 100 ng/mL were considered "suggestive toxicity".

149 Variables

150 The main variables of interest in this study were serum concentrations of 151 25-hydroxyvitamin D [25(OH)D], age, and the year of measurement. Vitamin D levels were classified as 'deficiency', 'insufficient' and 'sufficient' based on 152 recognized clinical thresholds. We further classified "Suggestive toxicity" when the 153 values were >100 ng/mL, and "Inadequate levels" when the values were deficient 154 or insufficient. Age was stratified into four categories: 'Children and adolescents', 155 'Young adults', 'Middle-aged adults' and 'Older adults'. The year of measurement 156 was used to compare vitamin D levels before and after the start of the COVID-19 157 158 pandemic. We also considered two outcome variables: 'Suggestive toxicity' and 'Inadequate levels'. 159

160 Statistical analysis

Descriptive statistics were first calculated to summarize the basic characteristics of the data set, including means and standard deviations for continuous variables, and frequencies and percentages for categorical variables. We stratified the analyzes by age group and by year of measurement to assess temporal trends in 25-hydroxyvitamin D (25(OH)D) levels. Chi-square tests were used to examine differences in the distribution of categorical variables between different groups. For continuous variables, independent samples t tests or Mann-Whitney U tests were

used, as appropriate. A p-value of less than 0.05 was considered statistically 168 significant. To further explore the relationships between age, year of measurement, 169 170 and 25-hydroxyvitamin D (25(OH)D) levels, cross-tabulations were performed. These analyzes were used to identify the prevalence of 25-hydroxyvitamin D 171 172 (25(OH)D) deficiency, insufficiency, sufficiency, suggestive toxicity, and inadequate levels within each age group and year. Results are reported as mean ± standard 173 174 deviation (SD) for continuous variables and number (percent) for categorical 175 variables, unless otherwise stated.

Two secondary analyses were performed: First, within a subsample of participants 176 to investigate possible selection bias in the study results. The association between 177 self-reported illnesses and inadequate 25-hydroxyvitamin D (25(OH)D) levels was 178 assessed using a chi-square test. Medical conditions were self-reported using the 179 personal data form, and this information was integrated into the laboratory's 180 database, along with data on medication use and comorbidities. Second, a 181 182 secondary analysis was performed to compare 25-hydroxyvitamin D (25(OH)D) levels between cities located at different altitudes: Quito, Ambato, and Ibarra, 183 located above 2,500 masl, and Santo Domingo, located below 625 masl. The chi-184 square test was used to examine the association between city location and 185 186 inadequate vitamin D levels.

187 To examine the potential change in average 25-hydroxyvitamin D (25(OH)D) concentration before and after March 2020 (pre-pandemic and pandemic periods). 188 a multiple linear regression analysis was employed. The independent variables in 189 the analysis included the passage of time (measured in months), a binary variable 190 indicating the period after March 2020, and an interaction term combining these 191 two variables. The dependent variable was the average monthly 25-hydroxyvitamin 192 193 D (25(OH)D) concentration. The total sample size for the regression analysis was 49. 194

For the statistical analysis, a Poisson regression model was utilized to determine the prevalence ratios for two health outcomes, namely toxicity and inadequate levels of 25-hydroxyvitamin D (25(OH)D), over a four-year period (2018-2021). For

198 each outcome, the year of observation was included as a categorical independent

variable, and prevalence ratios were estimated in relation to the base year of 2018.

200 Observations from the year 2022 were excluded from the analysis.

All statistical analyzes were performed using Stata 15.1 (Stata Corp. 2015. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP). A significance level of p<0.05 was considered statistically significant, indicating the presence of significant differences between the groups.

205 Ethical issues

The study protocol (CEISH 659-2022) received ethical approval from the Ethics Committee for Research in Human Beings of the Pontifical Catholic University of Ecuador, following an expedited review process.

209 Results

Descriptive results from the total sample are shown in **Table 1.** In this study 210 population of n=9286, most participants were female (74.65%). The mean age of 211 the population was 51.58 years (\pm 23.00), and the age range varied from 1-2 years 212 213 to 100-130 years. The mean concentration of 25-hydroxyvitamin D (25(OH)D) was 27.53 ng/mL (± 14.11). Regarding 25-hydroxyvitamin D (25(OH)D) levels, 64.58% 214 215 of the participants had inadequate levels, defined as a concentration of 25hydroxyvitamin D (25(OH)D) below 20 ng/mL. In addition, suggestive toxicity, 216 217 indicating potential harm due to excess 25-hydroxyvitamin D (25(OH)D), was present in 0.62% of the population, with a 25(OH)D concentration limit greater than 218 219 100 ng/mL. There was missing information because some participants did not provide their sex. The presented means and standard deviations provide more 220 221 information about the age distribution and 25-hydroxyvitamin D (25(OH)D) concentration within the study population. 222

Table 1: Demographics, 25-hydroxyvitamin D (25(OH)D) Levels, and Inadequate and

Suggestive Toxicity of 25-hydroxyvitamin D (25(OH)D) of the Study Population
 (N=9286)

It is made available under a CC-BY-ND 4.0 International license .

Variable Statistics					
Sex					
Female, n (%)	6932 (74.65%)				
Male, n (%)	2318 (24.96%)				
Not registered, n (%)	36 (0.39%)				
Mean Age (± SD)	51.58 years (± 23.00)				
Age Range (Years)					
1-2, n (%)	34 (0.37%)				
3-5, n (%)	93 (1.01%)				
6-11, n (%)	275 (2.98%)				
12-17, n (%)	440 (4.76%)				
18-65, n (%)	5630 (60.92%)				
66-79, n (%)	1685 (18.23%)				
80-99, n (%)	1070 (11.58%)				
100-130, n (%)	14 (0.15%)				
Mean 25-hydroxyvitamin D (25(OH)D)					
Concentration (± SD) 27.53 ng/mL (± 14.11)					
Inadequate 25-hydroxyvitamin D (25(OH)D)					
Level					
Yes, n (%)	5997 (64.58%)				
Suggestive Toxicity					
Yes, n (%)	58 (0.62%)				
Notes:					
1. Inadequate 25-hydroxyvitamin D (25(OH)D) Lo	evel was defined as having a concentration of				
 Suggestive Toxicity was defined based on the harm or risk due to excess 25-hydroxyvitamin 	presence of symptoms indicating potential D (25(OH)D), as ascertained by medical				
evaluation, and when the concentration of 25-hydroxyvitamin D (25(OH)D) exceeded 100					
ng/mL. 3. Participants who did not disclose their gender	are listed as 'Not Disclosed' under the 'Sex'				
category.					
4. Age is categorized into ranges for easier data	interpretation.				
 The means for age and 25-hydroxyvitamin D (25(OH)D) concentration are presented with their respective standard deviations 					

Additionally, regarding the two secondary analyses, First, in the subsample analysis, no significant differences were found in inadequate 25-hydroxyvitamin D

226

It is made available under a CC-BY-ND 4.0 International license .

229 (25(OH)D) levels between those without self-reported diseases (63%), those without any medication (64%), those with any self-reported disease (64%), and 230 231 those taking any medication (61%) (S1 Table). Inadequate levels were considered 232 based on specific criteria related to Vitamin D status. These findings suggest that 233 the results of our study are more generalizable to the general population from which the sample was drawn, since there does not seem to be a selection bias 234 235 related to the presence of diseases. Furthermore, when comparing 25hydroxyvitamin D (25(OH)D) levels between cities located at different altitudes: 236 237 Among the participants from Quito, Ambato and Ibarra, 64.18% had inadequate levels, while 52.74% of the participants from Santo Domingo had inadequate levels 238 239 (chi-square = 18.1854, p < 0.001). These findings suggest that altitude may play a role in 25-hydroxyvitamin D (25(OH)D) status, as people residing at higher 240 altitudes are more likely to have inadequate levels. 241

242 Regarding the evolution of concentration of 25-hydroxyvitamin D (25(OH)D) across 243 years, (S2Table) provides an overview of 25-hydroxyvitamin D (25(OH)D) levels, suggestive toxicity, and inadequate levels in different years and age groups. In 244 2018, a significant difference in the prevalence of deficiency was observed 245 between age groups, with the highest proportion in children and adolescents 246 (42.9%), followed by young adults (43.0%), middle-aged adults (20.4%) and older. 247 adults (33.0%). Similarly, in 2021 a significant difference was found, with the 248 249 highest proportion of deficiency in children and adolescents (29.1%), followed by older adults (26.1%), young adults (28.0%) and middle-aged adults (21.6%). 250 Regarding inadequate levels, the prevalence varied between years and age 251 groups, with the highest figures being observed in 2021 (2,695) and in the group of 252 253 middle-aged adults (1.099). Suggestive toxicity was identified in a small number of cases, mainly in older adults. In general, there was a significant association 254 255 between the year and the prevalence of deficiency and inadequate levels of 25hydroxyvitamin D (25(OH)D), indicating variations over time. 256

We can observe the trend of monthly average plasma of 25-hydroxyvitamin D (250HD) concentration during the pre-pandemic and pandemic periods. During the

pandemic period, although the values of 25-hydroxyvitamin D (25OHD) remain
inadequate, there is an evident increase in the monthly average concentration of
25-hydroxyvitamin D (25OHD). It increases from 2.4 ng/mL in 2018 to 2022 (Figure
1).



263

Figure 1. Monthly mean 25-hydroxyvitamin D (250HD) concentration pre-pandemic and pandemic period.

The results of the regression analysis (Table 2) revealed that there was a 266 statistically significant average monthly increase in 25-hydroxyvitamin D (25(OH)D) 267 concentration of 0.133 units (p=0.006). The period after March 2020, compared 268 with the period before March 2020, was associated with a non-significant reduction 269 in mean 25-hydroxyvitamin D (25(OH)D) concentration of 1.605 units (p=0.477). 270 However, the interaction between the period after March 2020 and time was not 271 272 significant (p=0.909), suggesting that there was no additional monthly change in 25-hydroxyvitamin D (25(OH)D) concentration after March 2020 beyond the 273 increase. overall monthly. The constant term indicated a significant baseline mean 274 25-hydroxyvitamin D (25(OH)D) concentration of 24.004 units at the start of the 275

276	study (p<0.001). The general model explained approximately 40.28% of the
277	variation in the average monthly concentration of 25-hydroxyvitamin D (25(OH)D)
278	(R-squared=0.4028, R-squared=0.3629) and was statistically significant (F=10.12,
279	p <0.001).

Table 2: Regression analysis of monthly average 25-hydroxyvitamin D (25(OH)D) concentration, before and after March 2020.

		Coefficient		
	Variable	(Average Monthly 25- hydroxyvitamin D (25(OH)D) concentration)	t statistic	p-value
Ti	ime* (per each month)	0.133	2.90	0.006
P	ost-March 2020** (1)	-1.605	-0.72	0.477
P(2(ost-March 020*Time***	0.008	0.11	0.909
C	onstant****	24.004	33.94	<0.001

* The "Time" coefficient refers to the average monthly increase in 25-hydroxyvitamin D (25(OH)D) concentration across all participants in the study.

****** "Post-March 2020 (1)" is the average difference in 25-hydroxyvitamin D (25(OH)D) concentration for all months after March 2020 (the 27th month of the study), compared to the months before March 2020.

******* "Post-March 2020*Time" is the interaction term, representing any additional monthly change in Vitamin D concentration after March 2020, beyond the general monthly increase.

********The Constant term represents the average 25-hydroxyvitamin D (25(OH)D) concentration at the start of the study (Time = 0).

282

The proportion of toxicity across 2018 to 2021 increased significantly and the 283 284 inadequate levels of 25-hydroxyvitamin D (25(OH)D) reduces in the same period, but with a non-significant change (S3, S4 Tables). These findings highlight the 285 presence of a general upward trend in 25-hydroxyvitamin D (25(OH)D) 286 concentration over time, but no additional significant monthly change after the 287 onset of the COVID-19 pandemic in March 2020. Results from the regression 288 model Poisson tests indicate a significant increase in the prevalence of toxicity 289 (Table 3) during the period from 2018 to 2021. Specifically, the prevalence of 290

It is made available under a CC-BY-ND 4.0 International license .

toxicity was found to be 6.53 times higher in 2020 and 7.37 times higher in 2021
compared to the base year 2018. In contrast, the prevalence of inadequate 25hydroxyvitamin D (25(OH)D) levels (**Table 4**) showed a slight but not statistically
significant decrease over the same period. The prevalence was found to be 3.5%
lower in 2020 and 8% lower in 2021 compared to 2018. These findings suggest
divergent trends in the two health outcomes over the study period.

297 Table 3: Poisson Regression Results for Toxicity* (2019-202)	297	Table 3: Poisson	Regression	Results for	Toxicity*	(2019-2021
--	-----	-------------------------	------------	-------------	-----------	------------

Year	Coefficient	Standard Error	z-statistic	P-value	Prevalence Ratio
2019	-0.5614968	1.414.213	-0.40	0.691	0.57
2020	1.876.703	1.027.402	1.83	0.068	6.53
2021**	1.997.484	1.013.072	1.97	0.049	7.37

*Suggestive Toxicity was defined based on the presence of symptoms indicating potential harm or risk due to excess 25-hydroxyvitamin D (25(OH)D), as ascertained by medical evaluation, and when the concentration of 25hydroxyvitamin D (25(OH)D) exceeded 100 ng/mL.

**The positive coefficient suggests a positive relationship between the year 2021 and toxicity, the p-value < 0.05, indicating statistical significance.

298

299 Table 4: Poisson Regression Results for Inadequate Vitamin D Level* (2019-2021)

Year	Coefficient	Standard Error	z-statistic	P-value	Prevalence Ratio
2019**	0.0111135	0.0524749	0.21	0.832	1.01
2020**	-0.0359239	0.0492221	-0.73	0.465	0.965
2021**	-0.0830686	0.0461695	-1.80	0.072	0.92
* Inadaguata DE	budrova wite min l		alwaa dafinad aa	having a sansar	tration of OF

* Inadequate 25-hydroxyvitamin D (25(OH)D) Level was defined as having a concentration of 25hydroxyvitamin D (25(OH)D) less than 20 ng/mL.

** These results suggest that there is no strong and consistent evidence for significant changes in the prevalence of inadequate vitamin D levels across the years 2019, 2020, and 2021.

300

301 Discussion

302 Main findings

303 This study revealed a high prevalence of inadequate levels of 25-hydroxyvitamin D

304 (25(OH)D) (64.58%) among individuals attending a private laboratory in Quito,

305 Ecuador. These findings align with a meta-analysis conducted between 2000 and 2022, which estimated the global and regional prevalence of deficiency in serum 306 307 25-hydroxyvitamin D levels. The meta-analysis included 308 studies with 7,947,359 participants from 81 countries, finding that 15.7% had levels below 12 308 ng/dL and 47.9% had levels below 20 ng/dL. Although the prevalence slightly 309 decreased from 2000-2010 to 2011-2022, it remained at a high level[10]. 310 311 Similarly, another meta-analysis conducted in an Asian population, including 746,564 subjects, reported that 22.82% had levels below 12 ng/dL and 57.69% 312 313 had levels below 20 ng/dL, indicating a high prevalence of 25-hydroxyvitamin D (25(OH)D) deficiency in Asia. 25-hydroxyvitamin D (25(OH)D) levels varied based 314 315 on gender, age group, region, altitude, and disease. Several factors contributed to these results, including dietary habits. Vitamin D is only present in a few foods, 316 317 such as fish liver oil and fatty fish, which are not commonly consumed by Asians, especially central Asians. Additionally, Asians tend to prefer a lighter skin color, 318 319 leading to the use of sunscreen and parasols outdoors, which reduces the penetration of ultraviolet B (UVB) and subsequently decreases vitamin D synthesis. 320 Clothing habits also play a significant role, as many individuals in western and 321 southern Asia, where Muslim populations reside, wear long robes and veils that 322 cover the skin. Moreover, people living in southern and Southeast Asia generally 323 have darker skin, which can block UVB penetration. Economic development also 324 influences vitamin D levels, particularly in Asian countries that are still developing 325 and lack access to effective vitamin D supplements[10]. 326

another 327 Furthermore, meta-analysis estimated the prevalence of 25hydroxyvitamin D (25(OH)D) deficiency in Africa. This analysis included 119 328 329 studies with 21,474 participants from 23 countries. The findings indicated that 18.46% had values below 12 ng/dL and 34.22% had values below 20 ng/dL. The 330 331 prevalence of 25-hydroxyvitamin D (25(OH)D) deficiency exhibited regional variation, with the highest rates observed in northern African countries and South 332 Africa[11]. Among population subgroups, women, newborn babies, and urban 333 populations had the lowest concentrations of 25(OH)D. Notably, populations living 334 335 in urban areas exhibited lower 25(OH)D concentrations compared to rural

It is made available under a CC-BY-ND 4.0 International license .

populations, potentially due to limited sunlight exposure duration or reduced dietary
intake of vitamin D. Conversely, the populations in Africa that practiced traditional
lifestyles, including nomadic animal rearing, hunting, and gathering, demonstrated
the highest 25(OH)D concentrations[11].

In a meta-analysis that estimated the prevalence of 25-hydroxyvitamin D 340 (25(OH)D) deficiency in South America, 96 studies with a total of 227,758 341 participants were included from an initial pool of 9,460 articles. The overall 342 prevalence of 25-hydroxyvitamin D (25(OH)D) deficiency, defined by a 25(OH)D 343 concentration below 20 ng/mL, was found to be 34.76%. Lifestyle factors such as 344 spending more time indoors for work, leisure, and physical activities, coupled with 345 dietary patterns and public health campaigns that promote sunlight avoidance and 346 skin protection, likely contribute to the lower-than-expected concentrations of 347 25(OH)D in this region[5]. 348

349 Ecuador, situated in the tropical zone, is longitudinally crossed by the Andes mountain range, which imparts distinct and prominent topographical characteristics 350 throughout the country. The altitude of Ecuador's regions holds significant influence 351 over various health outcomes experienced by its population[12]. Within the scope 352 353 of this study, a pronounced disparity in inadequate 25-hydroxyvitamin D (25(OH)D) levels was observed in laboratory results obtained from individuals residing in 354 355 Quito, positioned at an approximate elevation of 2,850 meters above sea level, in comparison to samples collected from individuals in Santo Domingo, situated at a 356 lower altitude of approximately 625 meters above sea level. Upon comparing 357 participants from Quito, Ambato, and Ibarra with those from Santo Domingo, it was 358 found that 64.18% of individuals from higher-altitude cities exhibited inadequate 359 25-hydroxyvitamin D (25(OH)D) levels, whereas the percentage was 52.74% 360 361 among those from Santo Domingo. These findings indicate a potential correlation between altitude and 25-hydroxyvitamin D (25(OH)D) status, suggesting that 362 individuals inhabiting higher altitudes are more susceptible to insufficient levels of 363 this nutrient. Therefore, it is crucial to consider regional factors when evaluating 25-364 hydroxyvitamin D (25(OH)D) status and devising appropriate interventions. These 365

results align with other studies, including research conducted in Asia by Zhiwei 366 Jiang, which revealed that individuals residing at lower altitudes (≤500 m) tend to 367 368 exhibit higher 25-hydroxyvitamin D (25(OH)D) levels compared to those at higher altitudes (>500 m)[10]. Furthermore, it has been observed that people living in 369 370 high-altitude regions often encounter difficulties in accessing effective vitamin D supplements[10]. The studies conducted in South America have incorporated two 371 372 fundamental factors, namely altitude and diet, into their analyses. At higher altitudes, the atmosphere is thinner, resulting in reduced absorption of ultraviolet 373 374 radiation (UV levels increase by 10% to 12% with each 1000-meter increase in altitude)[5]. 375

The findings of this study revealed a significant prevalence of inadequate 25-376 hydroxyvitamin D (25(OH)D) levels in the population, while the incidence of 25-377 hydroxyvitamin D (25(OH)D) toxicity was relatively low (0.62%). Interestingly, 378 divergent changes were observed in these indicators during the study period. 379 380 Although inadequate levels showed a non-significant reduction, there was a notable increase in the prevalence of toxicity from 2018 to 2021. These results 381 underscore a concerning trend in the 25-hydroxyvitamin D (25(OH)D) status of the 382 population. These findings are consistent with a study conducted in Ireland that 383 aimed to investigate the impact of the COVID-19 pandemic on vitamin D status and 384 the usage of newly introduced vitamin D supplements. A trend analysis based on 385 laboratory data revealed a threefold rise in the yearly average of 25(OH)D during 386 the initial year of the pandemic, compared to previous analyses. This trend 387 388 suggests potential benefits for individuals with low vitamin D status but also highlights the risk for those with already high levels, especially considering the 389 390 increasing availability of high-dose supplements[6].

The increased consumption of vitamin D supplements by the general population, including therapeutic and high-dose formulations, without adequate medical supervision, can significantly elevate the risk of exogenous hypervitaminosis D, commonly known as vitamin D toxicity. This condition can manifest symptoms of hypercalcemia[13]. Therefore, it is essential to ensure that the intake of vitamin D

is monitored by healthcare professionals to prevent overdosing and the associatedsevere health consequences[3,14,15].

Excessive intake of vitamin D can lead to the accumulation of the nutrient in the body for extended periods, up to 18 months, resulting in chronic toxic effects such as nephrocalcinosis, hypercalcemia, and hypercalciuria. In the past, fortification of foods, such as milk, was recommended as a public health strategy to prevent vitamin D deficiency and low 25-hydroxyvitamin D (25(OH)D) status. However, cases of increased hypercalcemia associated with excessive intake of fortified foods have been reported[3,14,15].

405 During the pandemic, there was a notable interest in studying the relationship between 25-hydroxyvitamin D (25(OH)D) levels and COVID-19. A study aimed at 406 identifying if online search interest in vitamin D increased with the pandemic 407 burden and analyzing the accuracy of public health messaging regarding vitamin D 408 409 in online news articles found that a significant number of articles provided conflicting information or incorrectly advised supratherapeutic doses. This study 410 411 emphasizes the opportunity for public health organizations to capitalize on the increased interest in vitamin D during the pandemic and disseminate accurate 412 413 information to raise awareness[16].

However, it is important to acknowledge the limitations of this study. Important factors such as skin pigmentation, socioeconomic conditions, diet, sun exposure habits, cultural practices, and skin coverage with clothing were not considered in the analysis. These factors can influence 25-hydroxyvitamin D (25(OH)D) levels and should be considered in future research.

The results of this study reveal a high prevalence of 25-hydroxyvitamin D (25(OH)D) deficiency, indicating the need for strategies to prevent deficiency. However, the increase in toxicity also raises concerns and highlights the importance of rational prescribing of vitamin D supplements and educating the population to avoid self-medication. To optimize resource allocation and prioritize those at higher risk, it may be beneficial to focus vitamin D testing on specific

425 populations. Individuals with malabsorption syndromes, individuals undergoing 426 steroid therapy, or older adults who are confined to their homes are examples of 427 higher-risk groups. Assessing serum of 25-hydroxyvitamin D (25(OH)D) levels in 428 these cases can provide valuable clinical insights and inform appropriate 429 interventions.

430 Supporting Information

431 S1 Table: Prevalence of inadequate levels of Vitamin D among: (i) those who does not have self-

432 reported diseases, (ii) those who are not taking medications, (iii) those who have reported any

433 chronic disease, and (iv) those who are taking any medication.

Variable	n=919			
No self-reported diseases, n (%)	399 (63)			
No medications, n (%)	471 (64)			
Any self-reported disease, n (%)	181 (64)			
Any medication, n (%)	109 (61)			
Inadequate levels were defined as a 25-hydroxyvitamin D (25(OH)D) concentration below 20				
ng/mL.				

S2 Table: 25-hydroxyvitamin D (25(OH)D) levels, suggestive toxicity, and inadequate levels per year and age group. 434

		Age ranges							
Year	25-hydroxyvitamin D (25(OH)D)		3-5 (n=93)	6-11 (n=275)	12-17 (n=440)	18-65 (n=5630)	66-79 (n=1685)	80-99 (n=1070)	>99 (n=14)
	Mean concentration in ng/mL, mean (SD)	-	19.4 (8.0)	24.1 (17.0)	21.8 (10.9)	26.4 (12.0)	26.6 (10.4)	22.3 (9.6)	12.2 (4.6)
2018	Inadequate levels, n (%)*	-	11 (58)	27 (44)	38 (45)	311 (72)	93 (69)	78 (85)	3 (100)
	Suggestive of toxicity, n (%)**	-	-	1 (2)	-	-	-	-	-
	Mean concentration in ng/mL, mean (SD)	-	30.5 (10.7	28.4 (6.9)	27.7 (10.7)	26.3 (10.8)	25.9 (11.0)	24.3 (12.6)	-
2019	Inadequate levels, n (%)*	-	9 (39)	2 (5)	11 (19.7)	677 (71.9)	206 (76.0)	96 (76.8)	-
	Suggestive of toxicity, n (%)**	-	-	-	-	1 (0.1)	-	-	-
	Mean concentration in ng/mL, mean (SD	23.8 (13.4)	30.2 (16.3)	29.5 (15.3)	22.9 (8.6)	27.5 (14.4)	30.1 (17.6)	24.2 (16.7)	8 (-)
2020	Inadequate levels, n (%)*	4 (50)	2 (13)	11 (19)	34 (40)	989 (67)	255 (65)	202 (79)	2 (100)
	Suggestive of toxicity, n (%)**	-	-	1 (2)	-	10 (1)	4 (1)	3 (1)	-
	Mean concentration in ng/mL, mean (SD)	30.6 (12.6)	32.6 (10.2)	27.2 (11.0)	23.6 (10.9)	29.1 (14.7)	29.7 (16.2)	24.8 (15.5)	17.0 (12.6)
2021	Inadequate levels, n (%)*	5 (20)	-	25 (23)	79 (39)	1646 (65)	500 (62)	427 (77)	8 (89)
	Suggestive of toxicity**	-	-	-	1 (1)	21 (1)	10 (1)	6 (1)	-
	Mean concentration in ng/mL, mean (SD)	21.7 (-)	17.2 (10.6)	24.1 (6.4)	20.7 (6.8)	30.1 (11.6)	29.4 (9.8)	27.3 (15.7)	-
2022	Inadequate levels, n (%)*	-	1 (50)	3 (27.2)	4 (40)	138 (58)	45 (62)	26 (60)	-
	Suggestive of toxicity, n (%)**	-	-	-	-	-	-	-	-
* Inade	* Inadequate levels" when the values were; for children <20 ng/ml; for young adults <30 ng/ml; for pregnant women <20 ng/ml; and, for elderly people <30								

ng/ml
** 'Suggestive of toxicity' of vitamin D are not represented in this table. Toxicity generally occurs at 25(OH)D concentrations greater than 100 ng/ml.

It is made available under a CC-BY-ND 4.0 International license .

435 S3 Table: Annual Prevalence Rates of Vitamin D Toxicity (%).

Year	n	Prevalence Rate (%)	95% Confidence Interval		
2018	835	0.12	0.02 - 0.85		
2019	1464	0.07	0.01 - 0.48		
2020	2301	0.78	0.49 - 1.24		
2021	4305	0.88	0.64 - 1.21		
Toxicity generally occurs at 25(OH)D concentrations greater than 100 ng/ml.					

436

437 S4 Table: Proportion of patients with inadequate vitamin D levels per year

Año	n	Proporción	Intervalo de			
			connanza del 95 /6			
2018	835	0.68	0.65 - 0.71			
2019	1464	0.69	0.66 - 0.71			
2020	2301	0.66	0.64 - 0.68			
2021	4305	0.63	0.61 - 0.64			
Less than 20 ng/ml for general population and less than 30 ng/ml for older adults and						
pregnant women						

438

439 Footnotes:

440 Acknowledgment: The authors express their sincere appreciation to the 441 healthcare professionals at Zurita & Zurita Laboratories for their expert handling of 442 the samples, which significantly contributed to the accuracy of our study. 443 Furthermore, ChatGPT from OpenAI was utilized to improve the document's overall 444 writing quality. No AI was involved in the study design, data analysis, interpretation 445 or substantial writing and reviewing of the manuscript.

446 Funding statement: This research received no specific grant from any funding447 agency in the public, commercial or not-for-profit sectors.

- 448 Author Contributions
- 449 Conceptualization: Camilo Zurita-Salinas, Betzabé Tello, Iván Dueñas-Espín
- 450 Data curation: Iván Dueñas-Espín, Betzabé Tello, Camilo Zurita-Salinas

It is made available under a CC-BY-ND 4.0 International license .

- 451 Formal analysis: Iván Dueñas-Espín, Betzabé Tello, Camilo Zurita-Salinas
- 452 Investigation: Camilo Zurita-Salinas, Betzabé Tello, Iván Dueñas-Espín, Jeannete
- 453 Zurita, William Acosta, Cristina Aguilera León, Andrés Andrade-Muñoz, José
- 454 Pareja-Maldonado.
- 455 Methodology: Camilo Zurita-Salinas, Betzabé Tello, Iván Dueñas-Espín
- 456 Validation: Camilo Zurita-Salinas, Betzabé Tello, Iván Dueñas-Espín, Jeannete
 457 Zurita, William Acosta, Cristina Aguilera León, Andrés Andrade-Muñoz, José
 458 Pareja-Maldonado.
- 459 Writing original draft: Betzabé Tello, Iván Dueñas-Espín
- 460 Writing review & editing: Camilo Zurita-Salinas, Betzabé Tello, Iván Dueñas-
- 461 Espín, Jeannete Zurita, William Acosta, Cristina Aguilera León, Andrés Andrade-
- 462 Muñoz , José Pareja-Maldonado.
- 463 Declaration of interest: None
- 464 **Patient consent for publication**: Not required.
- 465 **Data-sharing statement:** Data are available upon reasonable request. All data 466 relevant to the study were included in the article.
- Ethics approval: The study protocol (CEISH 659-2022) received ethical approval
 from the Ethics Committee for Research in Human Beings of the Pontifical Catholic
 University of Ecuador, following an expedited review process.

470 **References**

- 471 1 Cashman KD. Vitamin D Deficiency: Defining, Prevalence, Causes, and
 472 Strategies of Addressing. Calcif. Tissue Int. 2020;106:14–29.
 473 doi:10.1007/s00223-019-00559-4
- 474 2 Melmed S, Auchus R, Goldfi A, *et al. Williams. Tratado de endocrinología*.
 475 14.ª edici. España: 2021.

It is made available under a CC-BY-ND 4.0 International license .

Gallagher JC, Rosen CJ. Vitamin D: 100 years of discoveries, yet
controversy continues. *lancet Diabetes Endocrinol* 2023;11:362–74.
doi:10.1016/S2213-8587(23)00060-8

479 4 Cui A, Zhang T, Xiao P, *et al.* Global and regional prevalence of vitamin D
480 deficiency in population-based studies from 2000 to 2022: A pooled analysis
481 of 7.9 million participants. *Front Nutr* 2023;10.
482 doi:10.3389/fnut.2023.1070808

- Mendes M, Gomes A, Araújo M, *et al.* Prevalence of vitamin D deficiency in
 South America: A systematic review and meta-analysis. *Nutr Rev* Published
 Online First: 2023. doi:10.1093/nutrit/nuad010
- Mckenna MJ, Lyons OC, Flynn MAT, *et al.* COVID-19 pandemic and vitamin
 D: rising trends in status and in daily amounts of vitamin D provided by
 supplements. *BMJ Open* 2022;**12**:1–8. doi:10.1136/bmjopen-2021-059477
- Rustecka A, Maret J, Drab A, *et al.* The impact of covid-19 pandemic during
 2020–2021 on the vitamin d serum levels in the paediatric population in
 warsaw, poland. *Nutrients* 2021;**13**. doi:10.3390/nu13061990
- Ruiz-garc A, Pallar V, Tur M, *et al.* Vitamin D Supplementation and Its Impact
 on Mortality and Cardiovascular Outcomes: Systematic Review and.
 2023;:1–16.
- Berger MM, Shenkin A, Schweinlin A, *et al.* ESPEN micronutrient guideline.
 Clin Nutr 2022;**41**:1357–424. doi:10.1016/j.clnu.2022.02.015

Cui X, Zhai Y, Wang S, *et al.* Effect of the COVID-19 Pandemic on Serum
Vitamin D Levels in People under Age 18 Years: A Systematic Review and
Meta-Analysis. *Med Sci Monit* 2022;**28**:1–9. doi:10.12659/MSM.935823

Mogire RM, Mutua A, Kimita W, *et al.* Prevalence of vitamin D deficiency in
Africa: a systematic review and meta-analysis. *Lancet Glob Heal*2020;8:e134–42. doi:10.1016/S2214-109X(19)30457-7

It is made available under a CC-BY-ND 4.0 International license .

- Robles Rodríguez JB, Pazmiño K, Jaramillo A, *et al.* Relación entre
 deficiencia de vitamina D con el estado nutricional y otros factores en
 adultos de la región interandina del Ecuador. *Perspect en Nutr Humana*2022;24:35–48. doi:10.17533/udea.penh.v24n1a03
- Muneer S, Siddiqui I, Majid H, *et al.* Practices of vitamin D supplementation
 leading to vitamin D toxicity: Experience from a Low-Middle Income Country. *Ann Med Surg* 2022;**73**:103227. doi:10.1016/j.amsu.2021.103227
- Amrein K, Scherkl M, Hoffmann M, *et al.* Vitamin D deficiency 2.0: an update
 on the current status worldwide. *Eur J Clin Nutr* 2020;**74**:1498–513.
 doi:10.1038/s41430-020-0558-y
- 513 15 Marcinowska-Suchowierska E, Kupisz-Urbanska M, Lukaszkiewicz J, *et al.*514 Vitamin D Toxicity a clinical perspective. *Front Endocrinol (Lausanne)*515 2018;9:1–7. doi:10.3389/fendo.2018.00550
- Heer RS, Sandhu P, Wenban C, *et al.* Vitamin D in the news: A call for clear
 public health messaging during Covid-19. *Nutr Health* 2022;**28**:733–9.
 doi:10.1177/02601060221090293

519